Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada: Cardiovascular Disease in COPD Patients
Section snippets
Background
The research on the prevalence of cardiovascular diseases or the incidence of hospitalization caused by cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD) has been limited. It is recognized, however, that patients with impaired pulmonary function have an elevated risk of cardiovascular disease 1, 2, 3, 4. Previous studies have examined the relationship between patients' forced expiratory volume (FEV1) and heart disease. Hole and colleagues stratified a survey
Data Source
The Province of Saskatchewan provides medical benefits to nearly all residents of Saskatchewan (99%), a population of about one million people (7). As a result, Saskatchewan Health, a provincial government department, has accumulated and maintains longitudinal databases of health care information. The centralized databases include health insurance registration data, physician claims, hospital separations, outpatient prescription drugs, and vital statistics, including date and cause of deaths
Results
The database COPD cohort represented 2.6% of the population in the eligible age groups in Saskatchewan, 2.3% of the women, and 3.0% of the men. The COPD database cohort and comparison group were both 46% female. Fewer females responded to the smoking survey, so their proportion in the survey results was 41% in the COPD group and 43% in the comparison group. Approximately three fourths of the patients in the database study were 65 years and older at their index date, including one quarter who
Discussion
This study provides population-based evidence of higher prevalence and incidence of hospitalization for major cardiovascular events among persons with COPD compared to those without COPD, both with and without adjustment for diagnostic history of cardiovascular risk factors. Most COPD is caused by smoking (20), the adverse cardiovascular effects of which have been amply demonstrated. Due to data limitations, we were not able to separate the cardiovascular effects of smoking from the effects of
Conclusion
Persons with diagnosed and treated COPD are at increased risk for hospitalizations and deaths due to cardiovascular diseases.
References (24)
- et al.
Statin use and the risk of breast cancer
J Clin Epidemiol
(2003) - et al.
Left ventricular dysfunction in deteriorating patients with chronic obstructive pulmonary disease
Chest
(1995) - et al.
Systemic effects of chronic obstructive pulmonary disease
Eur Respir J
(2003) - et al.
Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease
Intensive Care Med
(2003) - et al.
Lung function and risk of myocardial infarction and sudden cardiac death
N Engl J Med
(1976) - et al.
Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease
Circulation
(March 2003) - et al.
Impaired lung function and mortality risk in men and women: Findings from the Renfrew and Paisley prospective population study
BMJ
(1996) - et al.
Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease
Eur Respir J
(1997) - et al.
Health Databases in Saskatchewan
- et al.
Incidence of lactic acidosis in metformin users
Diabetes Care
(1999)
Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure
Arch Internal Med
A record linkage study of valproate and malformations in Saskatchewan
Can J Public Health
Cited by (546)
Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease
2024, Archivos de BronconeumologiaInvestigation of ocular microstructural changes according to disease severity in patients with chronic obstructive pulmonary disease
2023, Canadian Journal of OphthalmologyLong-term mortality in ischemic stroke patients with concomitant chronic obstructive pulmonary disease
2022, Journal of Stroke and Cerebrovascular DiseasesStrategies targeting the NO pathway to counteract extra-pulmonary manifestations of COPD: A systematic review and meta-analysis
2022, Nitric Oxide - Biology and Chemistry
This study was funded by Pfizer, Inc., and Boehringer-Ingelheim Pharmaceuticals. It is based in part on de-identified data provided by the Saskatchewan Department of Health. The interpretation and conclusions contained herein do not necessarily represent those of the Government of Saskatchewan or the Saskatchewan Department of Health.